A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

Provided is an antihypertensive agent that is safe and has a mild effect.

An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.

Polythioether polymers, sealants containing polythioether polymers, and compounds useful as stabilizing monomers in the manufacture of polythioether polymers are provided. In many embodiments the polymers and sealants demonstrate reduced risk of spoilage that may be caused by low temperature storage of the polymer or uncured sealant. Compounds useful as stabilizing monomers include compounds according to formula I: CH.sub.2CR.sup.1CHR.sup.2SR.sup.3SCHR.sup.4CR.sup.5CH.sub.2 [I] wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are independently selected from H, CH.sub.3 or C.sub.2H.sub.5, and wherein R.sup.3 is selected from divalent groups comprising 2-12 carbon atoms, 0-5 ether oxygen atoms and 0-5 thioether sulfur atoms, which may be straight, branched or cyclic.

Polythioether polymers, sealants containing polythioether polymers, and compounds useful as stabilizing monomers in the manufacture of polythioether polymers are provided. In many embodiments the polymers and sealants demonstrate reduced risk of spoilage that may be caused by low temperature storage of the polymer or uncured sealant. Compounds useful as stabilizing monomers include compounds according to formula I: CH.sub.2CR.sup.1CHR.sup.2SR.sup.3SCHR.sup.4CR.sup.5CH.sub.2 [I] wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are independently selected from H, CH.sub.3 or C.sub.2H.sub.5, and wherein R.sup.3 is selected from divalent groups comprising 2-12 carbon atoms, 0-5 ether oxygen atoms and 0-5 thioether sulfur atoms, which may be straight, branched or cyclic.

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): ##STR00001## wherein R.sub.1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): ##STR00002## wherein R2, R.sub.3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R.sub.2, R.sub.3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Disclosed are noncationic lipidoid nanoparticles (LNPs) for His-tagged protein delivery.